Amgen's earnings call highlighted continued strong financials, with adjusted EPS growth and substantial cash flow generation.  Key is the anticipated launch of Prolia, though the exact timing remains uncertain.  The call also emphasized the company's proactive approach to regulatory hurdles and evolving market dynamics, particularly regarding anemia management and healthcare reform, which are acknowledged as major uncertainties.
[1]
